These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cyclooxygenase-2 inhibitors in colorectal cancer.
    Author: Stoehlmacher J, Lenz HJ.
    Journal: Semin Oncol; 2003 Jun; 30(3 Suppl 6):10-6. PubMed ID: 12802790.
    Abstract:
    Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors are associated with decreased colorectal cancer incidence and mortality rate. A majority of animal studies provide strong evidence that prevention of intestinal tumors is more efficiently accomplished by COX-2 selective inhibition rather than by COX-1 suppression. The inducible COX-2 isoform is overexpressed in colorectal tissues and is associated with critical events of tumorigenesis. COX-2 expression correlates with expression of angiogenic factors and new blood vessel formation. Inhibition of COX-2 favors apoptosis and causes a dose-dependent decline of tumor growth and metastasis in these models. These data, together with the fact that COX-2 inhibitors cause less toxic side effects compared with nonselective nonsteroidal anti-inflammatory drugs, render these new compounds promising candidates in chemoprevention and treatment of colorectal cancer. Results from initial clinical trials suggest that COX-2 inhibitors may be able to reduce the polyp burden in patients with familial polyposis coli. However, further clinical studies are needed to evaluate whether COX-2 inhibition will be effective in all types of colorectal tumor tissues. This is especially true for neoplastic lesions that express COX-2 at a lower level (eg, hereditary nonpolyposis colorectal cancer) and for colorectal tumors of patients with inflammatory bowel disease. In summary, COX-2 inhibitors represent a new and very promising group of chemotherapeutic agents with great potential for both colorectal cancer prevention and treatment.
    [Abstract] [Full Text] [Related] [New Search]